Citations

Clear

3138 citation(s) found for "Smith, AM".

Inspiratory Muscle Strength is Related to Exertional Dyspnoea in Heart Failure with Preserved Ejection Fraction
Warner, Brit, Bruhn, Eric J., Olson, Thomas P. , Bissen, Thomas G. , Smith, Joshua R. , Smith, Joshua R. , Smith, Joshua R , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | July 21, 2023 | Volume: 25 | Issue: 9 | Pages: 1716-1717

10.1002/ejhf.2980 | PMID 37476916 Get It

Image-Decomposition-Enhanced Deep Learning for Detection of Rotor Cores in Cardiac Fibrillation
Shu, Yu , Smith, Tianqi Gao, Tolkacheva, Elena G. , Cheng, Changqing , Arunachalam, S P , Arunachalam, Shivaram P.

Mayo Clinic

IEEE Transactions on Biomedical Engineering | July 13, 2023 | Volume: 71 | Issue: 1 | Pages: 68-76

10.1109/tbme.2023.3292383 | PMID 37440380 Get It

Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain
Smith, Thomas J. , Wang, Eric J. , Loprinzi, Charles L. , Smith, Thomas J , Wang, Eric

Mayo Clinic

New England Journal of Medicine | July 12, 2023 | Volume: 389 | Issue: 2 | Pages: 158-164

10.1056/nejmra2110098 | PMID 37437145 Get It

Cancer Cachexia: ASCO Guideline Rapid Recommendation Update
Bohlke, Kari , Baracos, Vickie E. , Smith, Thomas J. , Loprinzi, Charles L. , Panel, for the Cancer Cachexia Expert, Fabbro, Egidio Del , Dixon, Suzanne , Herrstedt, Jørn , Lau, Harold , Tan, Winston , Roeland, Eric J , Bohlke, Kari , Baracos, Vickie E , Smith, Thomas J , Loprinzi, Charles , Roeland, Eric , Panel, for the Cancer Cachexia Expert, Bruera, Eduardo , Fallon, Marie , Platek, Mary, Rugo, Hope S.

Mayo Clinic

Journal of Clinical Oncology | July 12, 2023 | Volume: 41 | Issue: 25 | Pages: 4178-4179

10.1200/jco.23.01280 | PMID 37467399 Get It

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual . The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
Litton, Jennifer K. , Regan, Meredith M. , Pusztai, Lajos , Tolaney, Sara M. , Garrett‐Mayer, Elizabeth , Amiri‐Kordestani, Laleh , Basho, Reva , Boileau, Jean-François , Foster, Jared C. , Jacene, Heather A. , King, Tari A. , Mason, Ginny, O’Sullivan, Ciara C. , Prowell, Tatiana M. , Richardson, Andrea L. , Sepulveda, Karla A., Smith, Mary Lou , Tjoe, Judy A., Turashvili, Gulisa , Butler, Lynn Pearson, Schwartz, Elena I., Korde, Larissa A. , Rugo, Hope S , Tolaney, Sara , Garrett-Mayer, Elizabeth , Amiri-Kordestani, Laleh , Basho, Reva K , Best, Ana F , Boileau, Jean-Francois , Denkert, Carsten , Foster, Jared C , Harbeck, Nadia , Jacene, Heather A , O'Sullivan, Ciara Catherine , Prowell, Tatiana M , Turashvili, Gulisa , Woodward, Wendy A , Pusztai, Lajos , Rugo, Hope S.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2023 | Volume: 41 | Issue: 27 | Pages: 4433-4442

10.1200/jco.23.00435 | PMID 37433103 Get It

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points. METHODS The NeoSTEEP working group concentrated on neoadjuvant systemic therapy end points in clinical trials with efficacy outcomes—both pathologic and time-to-event survival end points—particularly for registrational intent. Special considerations for subtypes and therapeutic approaches, imaging, nodal staging at surgery, bilateral and multifocal diseases, correlative tissue collection, and US Food and Drug Administration regulatory considerations were contemplated. RESULTS The working group recommends a preferred definition of pathologic complete response (pCR) as the absence of residual invasive cancer in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0 per AJCC staging). Residual cancer burden should be a secondary end point to facilitate future assessment of its utility. Alternative end points are needed for hormone receptor–positive disease. Time-to-event survival end point definitions should pay particular attention to the measurement starting point. Trials should include end points originating at random assignment (event-free survival and overall survival) to capture presurgery progression and deaths as events. Secondary end points adapted from STEEP 2.0, which are defined from starting at curative-intent surgery, may also be appropriate. Specification and standardization of biopsy protocols, imaging, and pathologic nodal evaluation are also crucial. CONCLUSION End points in addition to pCR should be selected on the basis of clinical and biologic aspects of the tumor and the therapeutic agent investigated. Consistent prespecified definitions and interventions are paramount for clinically meaningful trial results and cross-trial comparison.
Tubular and Glomerular Size by Cortex Depth as Predictor of Progressive CKD after Radical Nephrectomy for Tumor
Đenić, Aleksandar , Gaddam, Mrunanjali , Moustafa, Amr A. , Mullan, Aidan F. , Luehrs, Anthony C. , Sharma, Vidit , Thompson, R. Houston, Alexander, Mariam P., Lerman, Lilach O. , Alexander, Mariam P. , Moustafa, Amr , Alexander, Mariam P , Lerman, Lilach O , Barisoni, Laura , Rule, Andrew D , Denic, Aleksandar , Mullan, Aidan , Luehrs, Tony C , Smith, Maxwell L. , Barisoni, Laura , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | July 11, 2023 | Volume: 34 | Issue: 9 | Pages: 1535-1545

10.1681/asn.0000000000000180 | PMID 37430426 Get It

Significance Statement Glomerular size differs by cortex depth. Larger nephrons are prognostic of progressive kidney disease, but it is unknown whether this risk differs by cortex depth or by glomeruli versus proximal or distal tubule size. We studied the average minor axis diameter in oval proximal and distal tubules separately and by cortex depth in patients who had radical nephrectomy to remove a tumor from 2019 to 2020. In adjusted analyses, larger glomerular volume in the middle and deep cortex predicted progressive kidney disease. Wider proximal tubular diameter did not predict progressive kidney disease independent of glomerular volume. Wider distal tubular diameter showed a gradient of strength of prediction of progressive kidney disease in the more superficial cortex than in the deep cortex. Background Larger nephrons are prognostic of progressive kidney disease, but whether this risk differs by nephron segments or by depth in the cortex is unclear. Methods We studied patients who underwent radical nephrectomy for a tumor between 2000 and 2019. Large wedge kidney sections were scanned into digital images. We estimated the diameters of proximal and distal tubules by the minor axis of oval tubular profiles and estimated glomerular volume with the Weibel–Gomez stereological model. Analyses were performed separately in the superficial, middle, and deep cortex. Cox proportional hazard models assessed the risk of progressive CKD (dialysis, kidney transplantation, sustained eGFR <10 ml/min per 1.73 m 2 , or a sustained 40% decline from the postnephrectomy baseline eGFR) with glomerular volume or tubule diameters. At each cortical depth, models were unadjusted, adjusted for glomerular volume or tubular diameter, and further adjusted for clinical characteristics (age, sex, body mass index, hypertension, diabetes, postnephrectomy baseline eGFR, and proteinuria). Results Among 1367 patients were 62 progressive CKD events during a median follow-up of 4.5 years. Glomerular volume predicted CKD outcomes at all depths, but only in the middle and deep cortex after adjusted analyses. Proximal tubular diameter also predicted progressive CKD at any depth but not after adjusted analyses. Distal tubular diameter showed a gradient of more strongly predicting progressive CKD in the superficial than deep cortex, even in adjusted analysis. Conclusions Larger glomeruli are independent predictors of progressive CKD in the deeper cortex, whereas in the superficial cortex, wider distal tubular diameters are an independent predictor of progressive CKD.
Artificial intelligence‐based reticulin proportionate area – a novel histological outcome predictor in hepatocellular carcinoma
Patil, Ameya , Salvatori, Rebecca , Smith, Lindsey , Jenkins, Sarah M. , Hartley, Christopher , Moreira, Roger K. , Cannon, Andrew , Hartley, Christopher P., Hartley, Christopher P , Graham, Rondell P.

Mayo Clinic

Histopathology | June 30, 2023 | Volume: 83 | Issue: 4 | Pages: 512-525

10.1111/his.15001 | PMID 37387193 Get It

Aims Reticulin stain is used routinely in the histological evaluation of hepatocellular carcinoma (HCC). The goal of this study was to assess whether the histological reticulin proportionate area (RPA) in HCCs predicts tumour‐related outcomes. Methods and results We developed and validated a supervised artificial intelligence (AI) model that utilises a cloud‐based, deep‐learning AI platform (Aiforia Technologies, Helsinki, Finland) to specifically recognise and quantify the reticulin framework in normal livers and HCCs using routine reticulin staining. We applied this reticulin AI model to a cohort of consecutive HCC cases from patients undergoing curative resection between 2005 and 2015. A total of 101 HCC resections were included (median age = 68 years, 64 males, median follow‐up time = 49.9 months). AI model RPA reduction of > 50% (compared to normal liver tissue) was predictive of metastasis [hazard ratio (HR) = 3.76, P = 0.004, disease‐free survival (DFS, HR = 2.48, P < 0.001) and overall survival (OS), HR = 2.80, P = 0.001]. In a Cox regression model, which included clinical and pathological variables, RPA decrease was an independent predictor of DFS and OS and the only independent predictor of metastasis. Similar results were found in the moderately differentiated HCC subgroup (WHO grade 2), in which reticulin quantitative analysis was an independent predictor of metastasis, DFS and OS. Conclusion Our data indicate that decreased RPA is a strong predictor of various HCC‐related outcomes, including within the moderately differentiated subgroup. Reticulin, therefore, may represent a novel and important prognostic HCC marker, to be further explored and validated.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Coveler, Andrew L. , Smith, David C. , Curti, Brendan D. , Goel, Sanjay , Kuzel, Timothy M. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Lee, Hun Ju , Heath, Elisabeth I. , Thompson, John A. , Ansari, Sahar , Jacquemont, Céline, Topletz‐Erickson, Ariel R. , Zhou, Peigen , Curti, Brendan , Goel, Sanjay , Phillips, Tycel , Mehta, Amitkumar , Markovic, Svetomir N. , Gajewski, Thomas Frank , Gopal, Ajay K. , Caimi, Paolo F. , Ansari, Sahar, Schmitt, Michael W. , Grilley‐Olson, Juneko E.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 29, 2023 | Volume: 11 | Issue: 6 | Pages: e005584

10.1136/jitc-2022-005584 | PMID 37385724 Get It

Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than other CD40 agonists. A first-in-human phase 1 trial was conducted to examine safety, pharmacokinetics, and pharmacodynamics of SEA-CD40 monotherapy in patients with advanced solid tumors and lymphoma. Methods SEA-CD40 was administered intravenously to patients with solid tumors or lymphoma in 21-day cycles with standard 3+3 dose escalation at 0.6, 3, 10, 30, 45, and 60 µg/kg. An intensified dosing regimen was also studied. The primary objectives of the study were to evaluate the safety and tolerability and identify the maximum tolerated dose of SEA-CD40. Secondary objectives included evaluation of the pharmacokinetic parameters, antitherapeutic antibodies, pharmacodynamic effects and biomarker response, and antitumor activity. Results A total of 67 patients received SEA-CD40 including 56 patients with solid tumors and 11 patients with lymphoma. A manageable safety profile was observed, with predominant adverse events of infusion/hypersensitivity reactions (IHRs) reported in 73% of patients. IHRs were primarily ≤grade 2 with an incidence associated with infusion rate. To mitigate IHRs, a standardized infusion approach was implemented with routine premedication and a slowed infusion rate. SEA-CD40 infusion resulted in potent immune activation, illustrated by dose dependent cytokine induction with associated activation and trafficking of innate and adaptive immune cells. Results suggested that doses of 10–30 µg/kg may result in optimal immune activation. SEA-CD40 monotherapy exhibited evidence of antitumor activity, with a partial response in a patient with basal cell carcinoma and a complete response in a patient with follicular lymphoma. Conclusions SEA-CD40 was tolerable as monotherapy and induced potent dose dependent immune cell activation and trafficking consistent with immune activation. Evidence of monotherapy antitumor activity was observed in patients with solid tumors and lymphoma. Further evaluation of SEA-CD40 is warranted, potentially as a component of a combination regimen. Trial registration number NCT02376699.
Surgical Stabilization for Recurrent Patellar Instability in Competitive Wrestlers: Outcomes, Reoperations, and Return to Play at 6-Year Mean Follow-up
Feroe, Aliya G. , Smith, John-Rudolph H. , Stuart, Michael J. , Camp, Christopher L. , Krych, Aaron J. , Smith, John R. , Marigi, Erick M. , Stuart, Michael J , Camp, Christopher L. , Krych, Aaron J , Smith, John-Rudolph , Hevesi, Mario

Mayo Clinic

The American Journal of Sports Medicine | June 29, 2023 | Volume: 51 | Issue: 10 | Pages: 2608-2616

10.1177/03635465231182143 | PMID 37382294 Get It

Background: The extent to which recurrent patellar instability (RPI) affects wrestlers has not been thoroughly examined. Purpose: To assess return to wrestling (RTW), patient-reported outcomes, and reoperation rates after patellofemoral stabilization surgery (PFSS) for RPI in a cohort of competitive wrestlers. Study Design: Cohort study; Level of evidence, 3. Methods: All competitive wrestlers with a history of RPI and subsequent PFSS performed at a single institution between 2000 and 2020 were identified. Primary PFSS procedures included medial patellofemoral (MPFL) reconstruction (n = 31; 50%); MPFL repair (n = 22; 35.5%); or other PFSS (n = 9; 14.5%), such as tibial tubercle osteotomy, lateral retinacular release, and/or medial retinacular reefing. Exclusion criteria included revision PFSS or concomitant anterior cruciate ligament reconstruction or multiligament knee injury. Surgical failure was defined as subsequent patellar dislocation despite operative management or need for secondary PFSS. Results: Ultimately, 62 knees in 56 wrestlers with a mean age of 17.0 years (range, 14.0-22.8 years) were included at a mean follow-up of 6.6 years (range, 2.0-18.8 years). RTW occurred in 55.3% of wrestlers at a mean ± SD 8.8 ± 6.7 months. Among PFSS types, no differences were observed in rates of RTW ( P = .676), postoperative pain ( P = .176), Tegner activity level ( P = .801), International Knee Documentation Committee ( P = .378), Lysholm ( P = .402), or Kujala scores ( P = .370). RPI was the most common postoperative complication (n = 13; 21.0%). MPFL reconstruction had the lowest rate of RPI (6.5% vs 27.3% [repair] vs 55.6% [other]; P = .005) and surgical failure (9.7% vs 31.8% [repair] vs 55.6% [other]; P = .008). Kaplan-Meier survivorship free from surgical failure of the entire cohort was 91.9% at 1 year, 77.7% at 5 years, and 65.7% at 15 years. MPFL reconstruction had the highest survivorship when compared with MPFL repair and other PFSS up to 10 years after the index surgery (90.3% vs 64.1% vs 27.8%; P = .048). Conclusion: RPI remains a concern for competitive wrestlers after PFSS. MPFL reconstruction may serve as a more durable surgical treatment option with lower rates of RPI and failure when compared with other PFSS procedures at up to 10 years after surgery.